Short Interest in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Declines By 59.4%

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) was the target of a significant decrease in short interest in the month of June. As of June 15th, there was short interest totaling 1,568 shares, a decrease of 59.4% from the May 31st total of 3,862 shares. Based on an average daily trading volume, of 106,636 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

A number of analysts have commented on XTNT shares. Craig Hallum reaffirmed a “buy” rating on shares of Xtant Medical in a report on Wednesday, March 18th. BTIG Research restated a “buy” rating and issued a $1.00 price target on shares of Xtant Medical in a research report on Wednesday, May 13th. Two analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Xtant Medical currently has a consensus rating of “Buy” and a consensus price target of $1.00.

Xtant Medical Trading Up 1.4%

Shares of NYSEAMERICAN:XTNT traded up $0.01 during mid-day trading on Monday, reaching $0.43. The stock had a trading volume of 46,877 shares, compared to its average volume of 148,732. The firm has a 50 day simple moving average of $0.48 and a two-hundred day simple moving average of $0.57. Xtant Medical has a twelve month low of $0.40 and a twelve month high of $0.95. The firm has a market cap of $59.74 million, a PE ratio of 42.63 and a beta of -0.16. The company has a current ratio of 3.34, a quick ratio of 1.64 and a debt-to-equity ratio of 0.17.

Xtant Medical (NYSEAMERICAN:XTNT) last issued its earnings results on Wednesday, May 13th. The medical device company reported ($0.02) EPS for the quarter, meeting the consensus estimate of ($0.02). The firm had revenue of $20.88 million during the quarter, compared to the consensus estimate of $20.16 million. Xtant Medical had a net margin of 1.50% and a return on equity of 3.68%.

Institutional Trading of Xtant Medical

Several hedge funds have recently added to or reduced their stakes in the business. Jane Street Group LLC bought a new position in Xtant Medical during the second quarter worth about $26,000. Tradition Wealth Management LLC acquired a new stake in shares of Xtant Medical during the fourth quarter worth about $79,000. Wiregrass Investment Management LLC bought a new position in shares of Xtant Medical during the 4th quarter valued at about $81,000. Mink Brook Asset Management LLC lifted its holdings in shares of Xtant Medical by 125.8% during the 2nd quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock valued at $81,000 after purchasing an additional 60,997 shares in the last quarter. Finally, Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Xtant Medical in the 4th quarter valued at approximately $220,000. Institutional investors and hedge funds own 69.33% of the company’s stock.

Xtant Medical Company Profile

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.